Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

ology, University Hospital, Uppsala. "In past randomized studies using either IL-2 alone or similar agents we have not seen evidence of significant benefit to the patients. The Maxamine results suggest the potential for a meaningful advancement in the care of AML patients."

Patients treated in their second or subsequent remission ("CR2+") historically have a poor prognosis with about 5% achieving long-term survival. The 13 CR2+ patients treated with Maxamine Therapy in the ongoing Phase II study have experienced a substantial increase in remission duration, highlighted by the following results updated as of September 1, 1998:

The median time to relapse for the CR2+ patients was 21 months, more than three times the six-month historic median.

Only 10-20% of AML patients under the current standard of care historically achieve remission inversions, the lengthening of subsequent remission times beyond the duration of their previous remissions. However, 8 of 11 (73%) of the evaluable CR2+ patients treated with Maxamine Therapy have achieved remission inversion.

Moreover, 38% of the CR2+ patients treated with Maxamine Therapy remain in leukemia-free remission.

Quality of Life during Maxamine Therapy

In the Phase II study, patients have administered more than 8,000 doses of Maxamine at home. No unexpected side effects from the drug have been identified during the study. The majority, 75%, of the evaluable patients have returned to work while taking Maxamine Therapy. The study results suggest that the administration of Maxamine Therapy at home as a remission therapy for AML is both safe and feasible.

"Quality of life is very important for AML patients during remission," said Dr. Brune. "The ability to provide remission therapy on an outpatient, at-home, basis is essential to allow the patients to maintain as closely as possible their normal lifestyle."

Maxamine Mechanism of Action

In many patients with chronic infectious

Contact: Amy Flood
415-677-4455 x211
Noonan/Russo Communications

Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:

(Date:2/19/2019)... ... 19, 2019 , ... NCPDP announced today that Dave deBronkart, ... will deliver the luncheon keynote on Tuesday, May 7, at its 2019 ... empowering partnerships between patients and their medical providers to NCPDP’s Annual Conference, May ...
(Date:2/19/2019)... ... , ... According to a recent study by Columbia University, more than 40% ... and only 26% of widows return to their pre-loss level of life satisfaction, according ... of the most tragic events that one can face. Consequently, many look for a ...
(Date:2/19/2019)... ... February 18, 2019 , ... AdventHealth Connerton is ... Solutions Footwear Sanitizing Stations to maximize infection control for patients and their families. ... as MRSA and C. difficile, which can be transmitted from the bottoms of ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Create Health, Wealth and Have the Life You Want!” (published by Balboa Press), ... with weight issues to release the pounds, reconnect to their dreams and attain ...
(Date:2/19/2019)... ... February 19, 2019 , ... STAR Institute for ... for occupational therapists beginning March 2019. The focus of the new program is to ... cases. The new Group Supervision Programs will be held on Zoom for five weekly ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... ... ExceleraRx Corporation announced today that St. Luke’s Health System has joined the ... the state of Idaho. , “We are very pleased to welcome St. ... Corp. “We believe St. Luke’s commitment to expanding and leveraging its pharmacy capabilities to ...
(Date:2/19/2019)... ... , ... The Jean Griswold Foundation, a nonprofit named for the founder of ... lives of seniors and others in the communities in which Griswold Home Care operates. ... couldn’t afford them. , “Each of these organizations have made such an ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... Florida, has completed his new book “Live Hard Die Young.” Dr. Oexner was ... practices chiropractic medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a ...
Breaking Medicine Technology:
Cached News: